December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Natera, Inc. - Common Stock (NQ:NTRA)

192.57 +5.73 (+3.07%)
Streaming Delayed Price Updated: 10:52 AM EDT, Mar 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Natera, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
News headline image
SignateraTM MRD Identifies Breast Cancer Patients Who Can Forgo Surgery
From Natera, Inc.
Via Business Wire
News headline image
Elanco, Tandem Diabetes, Fortrea, Natera, and Myriad Genetics Shares Plummet, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as in... 
Via StockStory
Topics Government Stocks
News headline image
Abbott Laboratories Finalizes $21 Billion Acquisition of Exact Sciences, Redefining the Future of Cancer Diagnostics
CHICAGO — In a move that fundamentally reshapes the global diagnostics landscape, Abbott Laboratories (NYSE: ABT) officially completed its $21 billion acquisition of Exact Sciences (NASDAQ: EXAS)... 
Via MarketMinute
Topics Supply Chain
Natera Inc. (NASDAQ:NTRA) Crushes Q4 Earnings Estimates with Strong Oncology Growth ↗
Via Chartmill
News headline image
1 Unprofitable Stock to Own for Decades and 2 Facing Headwinds
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, th... 
Via StockStory
News headline image
1 Cash-Heavy Stock to Target This Week and 2 We Question
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face c... 
Via StockStory
News headline image
NeoGenomics, Natera, and Amphastar Pharmaceuticals Shares Skyrocket, What You Need To Know
What Happened? A number of stocks jumped in the afternoon session after easing crude oil prices helped lift investor sentiment and reduce inflation worries. ... 
Via StockStory
Topics Economy Stocks
News headline image
This Biotech Stock Surged 75% Last Quarter and Pulled a New $9 Million Investment ↗
Vera Therapeutics develops clinical-stage therapies for serious immunological diseases, with a lead candidate targeting kidney disorders. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Life Sciences Supplier Has Plunged 50% in a Year, but One Fund Bought Up $28 Million More in Stock ↗
Avantor delivers laboratory materials and specialized services to biopharma, healthcare, and advanced technology clients worldwide. 
Via The Motley Fool
Topics Regulatory Compliance Supply Chain
News headline image
Two Publications Highlight Clinical Utility of Signatera™ in Anal and Rectal Cancers
From Natera, Inc.
Via Business Wire
News headline image
3 Growth Stocks to Add to Your Roster
Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived thr... 
Via StockStory
News headline image
3 Market-Beating Stocks to Target This Week
Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three ... 
Via StockStory
News headline image
Natera Announces Commercial Launch of Zenith™ Genomics for Rare Disease Diagnosis
From Natera, Inc.
Via Business Wire
News headline image
3 Healthcare Stocks to Target This Week
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have se... 
Via StockStory
News headline image
Natera (NTRA) Stock Trades Up, Here Is Why
What Happened? Shares of genetic testing company Natera (NASDAQ:NTRA). jumped 4.3% in the afternoon session after Canaccord Genuity reiterated its Buy rating... 
Via StockStory
Topics Economy
News headline image
3 Reasons Exelixis Stock Could Deliver Market‑Beating Returns Over the Next Decade ↗
The U.S.-based biotech specializes in treating cancers with small molecules, antibody-drug conjugates, and other biotherapeutics. 
Via The Motley Fool
Topics Lawsuit
News headline image
Why Natera (NTRA) Shares Are Falling Today
Shares of genetic testing company Natera (NASDAQ:NTRA). fell 8.3% in the afternoon session after the release of a key inflation report revealed prices paid to U.S. producers rose more than anticipated... 
Via StockStory
Topics Earnings Economy
News headline image
Signatera™ MRD Data at ASCO GU Highlights Potential Utility Across GU Cancers, Including for Bladder Preservation
From Natera, Inc.
Via Business Wire
News headline image
Natera (NTRA) Q4 2025 Earnings Call Transcript ↗
Natera (NTRA) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Natera Reports Fourth Quarter and Full Year 2025 Financial Results
From Natera, Inc.
Via Business Wire
News headline image
Natera Earnings: What To Look For From NTRA
Genetic testing company Natera (NASDAQ:NTRA). will be reporting results this Thursday afternoon. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence World Trade
News headline image
Successful Readout of Prospective Phase 2 SINERGY Trial Supports SignateraTM MRD-Guided Treatment in Head and Neck Cancer
From Natera, Inc.
Via Business Wire
News headline image
Billionaire Stanley Druckenmiller Is Betting Big on These 2 Stocks ↗
These two stocks are core holdings in the legendary investor's portfolio. 
Via The Motley Fool
Topics Artificial Intelligence Earnings
News headline image
Natera to Report its Fourth Quarter and Full Year Results on February 26, 2026
From Natera, Inc.
Via Business Wire
News headline image
Natera Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy Outcomes
From Natera, Inc.
Via Business Wire
News headline image
Natera Submits Signatera™ CDx PMA to FDA
From Natera, Inc.
Via Business Wire
News headline image
Natera Announces Completion of Enrollment in Randomized ACES-EMB Trial in Heart Transplantation
From Natera, Inc.
Via Business Wire
News headline image
Prospera™ Featured in Landmark Interventional Study Advancing Lung Transplant Care
From Natera, Inc.
Via Business Wire
News headline image
2 Cash-Producing Stocks to Consider Right Now and 1 Facing Headwinds
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
News headline image
Natera Publishes Clinical Validation of Latitude™ Tissue-Free MRD Test in Colorectal Cancer
From Natera, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.